Gediminas Vidugiris

This inventor holds 26 USPTO granted patents and 13 EPO patents, primarily in Biotechnology and RF Technology. Top assignee: Promega Corporation. Active years: 2010-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Gediminas Vidugiris. Retrieved from https://idiyas.com/inventor/gediminas-vidugiris

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 26

% Patents Active = 84.6

EPO Patents = 13 (Patent Applications = 14)

Average Co-Inventor Count = 7.0

ph-index = 7

Forward Citations = 258(Granted Patents)

Company Filing History:

26 out of 417

Promega Corporation

patents

Years Active: 2010-2023

Loading Chart...

Areas of Expertise:

Syntheticluciferases

Enhanced Light Output

Mutant Hydrolase Proteins

Biosensors

cAMP Detection

RF Point of Sale

RFID Systems

Delivery Method

Polynucleotides

Dehalogenase Proteins

Protease Biosensors

26 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11667950 - Syntheticluciferases with enhanced light output (2023-06-06),

2. 11365436 - Synthetic oplophorus luciferases with enhanced light output (2022-06-21),

3. 10844422 - Syntheticluciferases with enhanced light output (2020-11-24),

4. 10633690 - Synthetic oplophorus luciferases with enhanced light output (2020-04-28),

5. RE47599 - RF point of sale and delivery method and system using communication with remote computer and having features to read a large number of RF tags (2019-09-09),

6. 10246690 - Mutant hydrolase proteins with enhanced kinetics and functional expression (2019-04-02),

7. 10233485 - Synthetic oplophorus luciferases with enhanced light output (2019-03-19),

8. 9879306 - Luciferase biosensors for cAMP (2018-01-30),

9. 9873866 - Mutant dehalogenase proteins (2018-01-23),

10. 9777311 - [object Object] (2017-10-03),

11. 9757478 - Mutant protease biosensors with enhanced detection characteristics (2017-09-12),

12. 9593316 - Polynucleotides encoding mutant hydrolase proteins with enhanced kinetics and functional expression (2017-03-14),

13. RE46326 - RF point of sale and delivery method and system using communication with remote computer and having features to read a large number of RF tags (2017-02-27),

14. 9339561 - Mutant protease biosensors with enhanced detection characteristics (2016-05-17),

15. 9290794 - Mutant protease biosensors with enhanced detection characteristics (2016-03-22),

Title: Gediminas Vidugiris: Innovator in Synthetic Luciferase Technology

Introduction: Gediminas Vidugiris is a prolific inventor based in Fitchburg, Wisconsin, recognized for his significant contributions to the field of biotechnology. With an impressive portfolio of 26 patents, he has made notable advancements in the development of synthetic luciferases, which are crucial for various applications in biological research.

Latest Patents: Among his latest patents, Vidugiris has focused on creating synthetic luciferases with enhanced light output. One of his innovations includes a polynucleotide encoding a modified luciferase polypeptide that demonstrates at least 60% amino acid sequence identity to a wild-type luciferase. This modified polypeptide features at least one amino acid substitution, resulting in enhanced luminescence, signal stability, and protein stability compared to the wild-type version. Another patent involves the development of synthetic Oplophorus luciferases, which share similar enhancements in luminescence and stability, showcasing his commitment to pushing the boundaries of synthetic biology.

Career Highlights: Gediminas Vidugiris works at Promega Corporation, where he collaborates with a team of talented researchers and scientists. His work is instrumental in advancing the company's mission to provide cutting-edge solutions for life sciences and biotechnological applications. His dedication to innovation has positioned him as a key figure in the synthetic luciferase domain.

Collaborations: Throughout his career, Vidugiris has collaborated with notable coworkers, including Lance P. Encell and Paul Otto. Their collective expertise and teamwork contribute to the remarkable achievements and ongoing research efforts within their field, further enhancing the potential applications of synthetic luciferases.

Conclusion: Gediminas Vidugiris stands out as an inventor whose work is pushing the frontiers of biotechnology. His patents on synthetic luciferases indicate a bright future for innovations in this area. Continuous teamwork and collaboration at Promega Corporation will likely lead to even more groundbreaking inventions that benefit various scientific fields.

Profile summary based on public USPTO records.